Creating a new therapy using engineered T cells for kidney cancer
Developing TCR-T cell therapy in renal cell carcinoma
This study is exploring a new treatment that uses specially designed immune cells to find and kill kidney cancer cells, aiming to give patients with this type of cancer a better option for fighting their disease.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project ID | NIH-11012880 on NIH RePORTER |
What this research studies
This research focuses on developing a novel therapy that utilizes engineered T cells to target and destroy kidney cancer cells. By identifying specific tumor antigens that these T cells can recognize, the researchers aim to enhance the immune response against renal cell carcinoma. The approach involves activating tumor-infiltrating lymphocytes (TILs) from patients and testing their effectiveness against cancer cells in the laboratory. If successful, this therapy could provide a new treatment option for patients with this type of cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with renal cell carcinoma who have specific tumor antigens recognized by engineered T cells.
Not a fit: Patients with other types of cancer or those who do not express the targeted tumor antigens may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new, effective treatment for patients with renal cell carcinoma.
How similar studies have performed: Previous research has shown promise in using engineered T cell therapies for various cancers, indicating potential success for this approach in renal cell carcinoma.
Where this research is happening
Newark, UNITED STATES
- Rutgers Biomedical and Health Sciences — Newark, United States (Active)
Researchers
- Principal investigator: Chiou, Shin-Heng — Rutgers Biomedical and Health Sciences
- Study coordinator: Chiou, Shin-Heng
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.